These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29205059)

  • 1. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells.
    Moosavian SA; Abnous K; Akhtari J; Arabi L; Gholamzade Dewin A; Jafari M
    Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2054-2065. PubMed ID: 29205059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
    Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of aptamer 5TR1 in triple negative breast cancer target therapy.
    Luo S; Wang S; Luo N; Chen F; Hu C; Zhang K
    J Cell Biochem; 2018 Jan; 119(1):896-908. PubMed ID: 28671278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-targeting CD44 and mucin by hyaluronic acid and 5TR1 aptamer for epirubicin delivery into cancer cells: Synthesis, characterization,
    Jamshidi Z; Dehghan R; Nejabat M; Abnous K; Taghdisi SM; Hadizadeh F
    Heliyon; 2024 Jan; 10(2):e24833. PubMed ID: 38312665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
    Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
    J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
    Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
    Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 aptamer-targeted DNA micelles for dual tumor therapy using doxorubicin and KLA peptide.
    Charbgoo F; Alibolandi M; Taghdisi SM; Abnous K; Soltani F; Ramezani M
    Nanomedicine; 2018 Apr; 14(3):685-697. PubMed ID: 29317345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
    Amiri Darban S; Nikoofal-Sahlabadi S; Amiri N; Kiamanesh N; Mehrabian A; Zendehbad B; Gholizadeh Z; Jaafari MR
    Colloids Surf B Biointerfaces; 2018 Apr; 164():107-115. PubMed ID: 29413587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
    Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
    J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AR13 peptide-conjugated liposomes improve the antitumor efficacy of doxorubicin in mice bearing C26 colon carcinoma; in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Moosavi Baigi F
    Toxicol Appl Pharmacol; 2023 May; 466():116470. PubMed ID: 36933622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
    Amin M; Badiee A; Jaafari MR
    Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
    Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo.
    Jalalian SH; Taghdisi SM; Shahidi Hamedani N; Kalat SA; Lavaee P; Zandkarimi M; Ghows N; Jaafari MR; Naghibi S; Danesh NM; Ramezani M; Abnous K
    Eur J Pharm Sci; 2013 Oct; 50(2):191-7. PubMed ID: 23835028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity.
    Dadpour S; Mehrabian A; Arabsalmani M; Mirhadi E; Askarizadeh A; Mashreghi M; Jaafari MR
    IET Nanobiotechnol; 2022 Sep; 16(7-8):259-272. PubMed ID: 35983586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma.
    Shahraki N; Mehrabian A; Amiri-Darban S; Moosavian SA; Jaafari MR
    Colloids Surf B Biointerfaces; 2021 Apr; 200():111589. PubMed ID: 33545570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
    Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M
    Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.